Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: info@advancedenzymes.com, www.advancedenzymes.com

September 13, 2021

BSE Limited
Department of Corporate Affairs
P. J. Towers, Dalal Street,
Mumbai - 400 001
Scrip ID-540025

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Code-ADVENZYMES

Dear Sir/Madam,

Sub: Press Release

Please find enclosed copy of the Press Release dated September 13, 2021 and titled "Advanced Enzymes announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve 'Long Covid' Fatigue Symptoms". Also attached are press release in Hindi, Marathi and Gujarati languages and the presentation.

In this regard, the Company has also scheduled the virtual press conference today.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For Advanced Enzyme Technologies Limited

SANJAY PRAKASH BASANTANI
Digitally signed by SANJAY PRAKASH BASANTANI
Date: 2021.09.13 10:51:17 +05'30'

Sanjay Basantani
Company Secretary and Head – Legal

Encl.: As above

PRESS RELEASE

ADVANCED ENZYMES ANNOUNCES POSITIVE CLINICAL BREAKTHROUGH IN THE RANDOMIZED CONTROLLED TRIALS OF SYSTEMIC ENZYMES AND PROBIOTICS TO RESOLVE 'LONG COVID' FATIGUE SYMPTOMS

AETL has unleashed its Holy Grail regenerative systemic enzymes and probiotics supplements, which is incredibly effective for people suffering from 'Post COVID' fatigue symptoms.

HIGHLIGHTS:

- Randomized, multicentre, double blind and placebo-controlled clinical trials were conducted on 200 patients suffering from post COVID fatigue symptoms.
- The clinical trials were conducted in two segments—around 100 patients (test arm) were administered with oral supplements for 14-days, and rest 100 patients (control arm) were administered with placebo.
- The clinical efficacy was conducted as per the Chalder Fatigue Scale (CFQ-11) for 14-days.
- Clinical trials factored positive results in terms of resolution of fatigue in a greater proportion on patients during the test as against the control arm (91% vs. 15%).
- In August 2021, the company forayed into the E-commerce space with its flagship all natural, chemical-free COVID immunity management bundle — 'ImmunoSEB' and 'Biome ULTRA' in the US and Indian markets.

MUMBAI, SEPTEMBER 13, 2021: Advanced Enzyme Technologies Limited (AETL) (**NSE: ADVENZYMES; BSE: 540025**) today announced that its systemic enzyme and probiotic supplements—ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve post-COVID fatigue symptoms.

It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID-19 disease. However, there are no specific treatments available globally to treat post-COVID fatigue complications.

With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID-19 induced fatigue, a randomized, multi-centric, double blind and placebo-controlled trial was conducted in 200 patients suffering from post-COVID fatigue symptoms.

The test arm (100 patients) received the oral supplements for 14-days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL.

The randomized clinical trial was conducted on 200 patients that did not have an active SARS-CoV-2 infection, as determined by a negative COVID-19 test, with a complaint of post-COVID fatigue. Patients were required to have a positive COVID-19 test at any time in the past. The trial was conducted across three centres in India—Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14-days, informed Dr Rathi.

According to the clinical research paper published by the Switzerland-based "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ-11) for 14-days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14-day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14-day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post-COVID-19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi.

The Coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7–10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID.

Studies revealed that about 52 percent of patients among the studied population showed fatigue/myalgia post-COVID-19.

A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID-19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.

"Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomized clinical trials," said Mr. Vasant Rathi, Chairman, AETL.

"Recent trials suggest that nutraceuticals product supplement succours in recovery of COVID patients. However, the patient-oriented outcome of the supplement may vary in individuals. For some, they may find a difference within couple of days, but for others, it may take a week or ten days. To avail long-term benefit and better results of the supplement, it's advisable to take the immunity bundle doses consistently every day for couple of months. However, in case you miss the dosage, don't' worry as it has no side effects," said Mr. Rathi.

“We have served the Americans since over last 30 years. But during the pandemic, our key focus was to enhance immunity amongst Indians. Hence, we went online with our research-backed immunity bundle. I feel, doctors need to address the issue of post-COVID immunity soon as its affecting quality of life,” said Mr. Mukund Kabra, Director, Advanced Enzyme Technologies Limited (AET).

To benefit common people our researched-backed chemical-free post-COVID immune support bundle — ImmunoSEB and Biome Ultra (ProbioSEB CSC3), our company has beefed up our omnichannel presence across India and globally. We tasted our runaway success in the US markets amidst the pandemic, hence decided to list our flagship immune support brands across online marketplaces in India to target a larger swath of pill-fatigued, healthy agers, immunity conscious millennials, and Gen Z, said Mr Kabra.

Meanwhile, the products are currently available globally on the leading e-commerce marketplace — Amazon. In a move to further shore up its direct-to-customer (D2C) omnichannel retailing business, AETL has unveil its online store — 'Advanced Enzymes e-Direct Store' in September 2021 to help customers choose from a wide range of health support products.

ABOUT ADVANCED ENZYME TECHNOLOGIES LIMITED

Incorporated in 1989, Advanced Enzyme Technologies Limited (AET) is a research-driven global company with leadership in manufacturing enzymes and probiotics. The company offers eco-safe solutions to various industries, such as human health care & nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, and to name a few.

The company aims to supplant traditionally used chemicals with eco-friendly enzymatic solutions. It provides customized and effective enzyme solutions coupled with the best in technical advice and superior services. It has seven state-of-the-art manufacturing units and six R&D located across India, Germany, and the US. It exports to over 45 countries spread across six continents.

On January 11, 2021, AET acquired a majority stake in SciTech Specialties specializing in effervescent-based products for Rs.316 million. The acquisition synergized the company with two manufacturing facilities and one R&D facility. It led to a growth of 1.8 percent. Currently, the company has nine manufacturing units and seven R&D facilities.

FOR MORE INFORMATION, PLEASE CONTACT PRITTLE PRATTLE PR

Smruti Alinje Bhalerao I (+91) 96195 50143 I smruti@prittleprattle.in
Vidyut Kumar Ta I (+91) 8879041399 I vidyut@prittleprattle.in

PRESS RELEASE

एडवांस एंजाइम्स ने लंबे समय से चल रहे कोविड के थका देने वाले लक्षणों के निदान हेतु क्रम रहित नियंत्रित परीक्षणों के लिए प्रणालीगत तथा प्रोबियोटिक्स सकारत्मक क्लिनिकल खोज की घोषणा की

मुंबई, 13 सिंतबर, 2021: एडवांस एंजाइम टेक्नोलॉजिस लिमीटेड (एइटीएल) (एनएसइ एडीवीइएनवायएमइएस; बीएसइः 540025) ने आज उनके संपूर्ण और प्रोबियोटिक्स सप्लिमेन्ट्स- इम्युनोसेब और प्रोबियोसेब सीएससी3 द्वारा कोविड से उबरने के पश्ताच होने वाली लंबी थकान के लक्षणों के नियंत्रित करने के लिए प्रभावकारिता के संदर्भ में क्रम रहित नियंत्रित नैदानिक परीक्षणों को आशाजनक तौर पर पार कर लिया।

एइटीएल के मुख्य वैज्ञानिक डा. अभिजीत के राठी द्वारा कोविड-19 की बीमारी से पीड़ित हो चुके थके हुए 200 रोगियों में स्वास्थ्य पूरक इम्यूनोएसईबी (सिस्टमिक एंजाइम कॉम्प्लेक्स) और प्रोबियोएसईबी सीएससी3 (प्रोबायोटिक कॉम्प्लेक्स) की प्रभावकारिता और सुरक्षा का मूल्यांकन करने के उद्देश्य से एक क्रम रहित, बहु-केंद्रित, दोहरे ब्लाइंड और प्लेसीबो-नियंत्रित परीक्षण की जानकारी दी गई।

डा. राठी द्वारा दी गई जानकारी के अनुसार इन 200 रोगियों की भारत के तीन स्वास्थ्य केंद्रों स्वास्थ्य अस्पताल, भोपाल, संवेदना अस्पताल, वाराणसी और चिरायु मेडिकल कॉलेज एंड अस्पताल, भोपाल में 14 दिनों तक जांच की गई।

स्विट्जरलैंड के नैदानिक शोध पत्र "मेडिसिन्स" जर्नल द्वारा 30 अगस्त 2021 को प्रकाशित खबर के अनुसार इन रोगियों का चाल्डेर फॉतिग स्केल (CFQ-11) का उपयोग करके 14 दिनों तक उपचार के प्रभाव की तुलना की गई। डा. राठी ने बताया कि दिलचस्प बात यह हुई कि इस संपूर्ण उपचार के परिणाम स्वरुप इन 14 दिनों परीक्षण के दौरान रोगियों में थकान को (91% बनाम 15%) के बड़े अनुपात में कम करने में सफलता मिली, जो कि काफी उत्साहनवर्धक है।

एईटीएल के अध्यक्ष श्री वसंत राठी ने कहा, "एंजाइम और प्रोबायोटिक्स सहनशक्ति और जीवन शक्ति को पुनर्जीवित करने के लिए एक मजबूत तंत्र हैं, जो कि हाल ही में संपन्न क्रम रहित स्वास्थ्य परीक्षणों के दौरान साबित हुआ है।"

उन्होनें आगे बताया कि "हमारे शोध-समर्थित सभी प्राकृतिक, रासायनिक-मुक्त कोविड के पश्चात इम्यून बढ़ाने में मददगार इम्यूनोएसईबी और बायोम अल्ट्रा (प्रोबियोएसईबी सीएससी 3) जनता की भलाई के लिए हमारी कंपनी ने पूरे भारत और विश्व स्तर पर अपनी उपस्थिति को दर्ज कराया है। यह उत्पाद अमेज़न पर उपलब्ध है।

एईटीएल के पूर्णकालिक निदेशक श्री मुकुंद काबरा ने जानकारी दी कि महामारी के दौरान अमरीकी बाजार में मिली सफलता से उत्साहित हमारी कंपनी ने भारत में ऑनलाईन मार्केट के सभी जगहों पर अपने उत्पादन प्रतिरक्षा को बढ़ाने वाले ब्रांडों को सूचीबद्ध करने का फैसला किया है, जो कि अधिकतर टैबलेट के सेवन से परेशान, स्वस्थ उम्र को लोगों, स्वास्थ्य के प्रति जागरुक नागरिक और जेन जेड के लोगों को लक्षित का करने का लक्ष्य रखा गया है।

PRESS RELEASE

कोविडपश्चात काळात दीर्घकालीन थकवा लक्षणावर गुणकारी असलेल्या सिस्टेमिक एन्झाईम्स व प्रोबायोटिक्सच्या यादृच्छीक नियंत्रित चाचण्यांना सकारात्मक वैद्यकिय प्रतिसाद मिळाल्याची 'ॲडव्हान्सड् एन्झाईम्स'ची घोषणा

मुंबई, १३ सप्टेंबर २०२१ : ॲडव्हान्सड् एन्झाईम टेक्नॉलॉजीज लिमिटेड (एईटीएल) (एनएसई: **ADVENZYMES** बीएसई : **540025**) ने आज आपल्या 'इम्यूनोएसईबी' आणि 'प्रोबायोएसईबी सीएससी३' या सिस्टेमिक एन्झाईम व प्रोबायोटीक सप्लीमेंटनी **यादृच्छीक** नियंत्रण वैद्यकीय चाचण्यांची महत्वपूर्ण पायरी पूर्ण केल्याचे जाहीर केले आहे. या चाचण्या रुग्णांमधील कोविडपश्च्यात जी तणाव लक्षणे आढळतात त्यावरील प्रभावाच्या संदर्भातील आहेत.

कोविड-१९मुळे ज्या रुग्णांमध्ये थकवा जाणवतो त्यांच्यामधील 'इम्यूनोएसईबी' (सीस्टेमिक एन्झाईम कॉम्प्लेक्स) आणि 'प्रोबायोएसईबी सीएससी3' (प्रोबायोटीक कॉम्प्लेक्स) या पूरक औषधांची परिणामकारकता आणि सुरक्षितता तपासण्यासाठी ही चाचणी केली गेली. ही चाचणी यादृच्छीक, बहुकेन्द्री, दुपेडी आणि प्लॅसीडो नियंत्रित होती आणि ती ज्या रुग्णांमध्ये कोविडनंतर थकवा अनुभवायला येत होता, अशा २०० रुग्णांमध्ये केली गेली, अशी माहिती 'एईटीएल'चे प्रमुख शास्त्रज्ञ डॉ अभिजित के राठी यांनी दिली.

देशभरातील स्वास्थ्य रुग्णालय, भोपाळ; संवेदना रुग्णालय, वाराणसी आणि चिरायू मेडिकल कॉलेज व रुग्णालय, भोपाळ या तीन ठिकाणी २०० रुग्णांवर ही चाचणी केली गेली. ही चाचणी शास्त्रज्ञांकडून १४ दिवस केली गेली, असे ही डॉ राठी म्हणाले.

स्वित्झर्लंडस्थित 'मेडीसिन्स' या जर्नलने ३० ऑगस्ट २०२१ रोजी जो एक वैद्यकीय संशोधन प्रबंध प्रकाशित केला आहे, त्यानुसार उपचारांची परिणामकारकता ही 'चाल्डर फटिग स्केल' (सीएफक्यू ११) वापरून केली गेली होती आणि ती १४ दिवस वापरली गेली होती. विशेष म्हणजे, १४ दिवसांच्या या काळात 'कंट्रोल आर्म'शी (संबंधित औषधेविरहित कालावधी) तुलना करता या पूरक औषधोपचारांचा परिणाम असा झाला की रुग्णांमधील थकवा हा चाचणीदरम्यान मोठ्या प्रमाणावर कमी (९१% विरुद्ध १५%) झाला, असेही डॉ राठी यांनी म्हटले आहे.

एन्झाईम व प्रोबायोटिक्स ही आपली शक्ती व चेतना बलशाली करण्याची एक भक्कम यंत्रणा आहे आणि ही बाब नुकत्याच ज्या यादृच्छीक चाचण्या केल्या गेल्या त्यातून सिद्ध झाले आहे, असे उद्गार 'एईटीएल'चे अध्यक्ष श्री वसंत राठी यांनी काढले आहेत.

"संपूर्णतः नैसर्गिक, संशोधनाचे भक्कम पाठबळ असलेली रसायनमुक्त कोविड-पश्च्यात रोगप्रतिकारक औषधे 'इम्युनोएसईबी' आणि 'बायोमीअल्ट्रा' (प्रोबायोएसईबी सीएससी3) लोकांच्या हितासाठी कंपनीने संपूर्ण भारत आणि जागतिक स्तरावरील आमच्या सर्वसमावेशक अस्तित्त्वावर भर दिला आहे. ही उत्पादने भारतात ॲमॅझॉनवर उपलब्ध आहेत.

साथरोगाच्या काळात आम्ही अमेरिकेमध्ये आमच्या यशाची चाचणी केली आणि आणि त्यानंतर आम्ही आमचे प्रमुख रोगप्रतिकारकशक्ती वाढविणारे ब्रँड भारतात ऑनलाईन बाजारपेठेत आणायचे ठरवले. त्याद्वारे आम्ही गोळ्यांचा कंटाळा आलेले, सुदृढ वयोवृद्ध, रोगप्रतिकारक शक्तीबद्दल जागरूक असलेले विशीतील तरुण या मोठ्या वयोगटाला समोर ठेवून ही उत्पादने दाखल केली गेली आहेत," असे उद्गार 'एईटीएल'चे सार्वकालिक संचालक श्री मुकुंद काब्रा यांनी काढले.

PRESS RELEASE

એડવાન્સ એન્ઝાઈમ્સ દ્વારા કોવિડ પશ્ચાતનાં થાકનાં લક્ષણોનો ઉકેલ લાવવા માટે સિસ્ટમિક એન્ઝાઈમ્સ અને પ્રોબાયોટિક્સના અડસટ્ટે નિયંત્રિત પરીક્ષણોમાં હકારાત્મક ચિકિત્સકીય પ્રગતિની ઘોષણા

મુંબઈ, 13 સપ્ટેમ્બર, 2021- એડવાન્સ્ડ એન્ઝાઈમ ટેકનોલોજીઝ લિમિટેડ (એઈટીએલ) (**NSE: ADVENZYMES; BSE: 540025**) દ્વારા આજે તેનાં સિસ્ટમિક એન્ઝાઈમ અને પ્રોબાયોટિક પૂરકો- ઈમ્યુનો એસઈબી અને પ્રોબાયોએસઈબી સીએસસી૩ દ્વારા કોવિડ પશ્ચાત થાકનાં લક્ષણોનો ઉકેલ લાવવા માટે કાર્યસાધકતાની દષ્ટિએ અડસટ્ટે નિયંત્રિત ચિકિત્સકીય પરીક્ષણોનો આશાસ્પદ તબક્કો પસાર કર્યો હોવાની આજે ઘોષણા કરી હતી.

કોવિડ-19 પ્રેરિત થાકથી પીડાતા દર્દીઓમાં આરોગ્યનાં પૂરકો ઈમ્યુનો એસઈબી (સિસ્ટમિક એન્ઝાઈમ કોમ્પ્લેક્સ) અને પ્રોબાયોએસઈબી સીએસસી૩ (પ્રોબાયોટિક કોમ્પ્લેક્સ)ની કાર્યસાધકતા અને સુરક્ષાનું મૂલ્યાંકન કરવાના લક્ષ્ય સાથે અડસટ્ટે, બહુકેન્દ્રિત, ડબલ બ્લાઈન્ડ અને પ્લાસીબો- નિયંત્રિત પરીક્ષણ કોવિડ પશ્ચાત થાકનાં લક્ષણોથી પીડાતા 200 દર્દીઓમા હાથ ધરાયું હતું, એમ એઈટીએલના મુખ્ય વિજ્ઞાની ડો. અભિજિત કે રાઠીએ જણાવ્યું હતું.

આ અડસટ્ટે ચિકિત્સકીય પરીક્ષણ ભારતમાં ત્રણ કેન્દ્રોમાં 200 દર્દીઓ પર 14 દિવસો માટે તપાસકર્તાઓ દ્વારા હાથ ધરાયું હતું, જેમાં સ્વાસ્થ્ય હોસ્પિટલ- ભોપાલ, સંવેદના હોસ્પિટલ- વારાણસી અને ચિરાયુ મેડિકલ કોલેજ એન્ડ હોસ્પિટલ, ભોપાલનો સમાવેશ થતો હતો.

30 ઓગસ્ટ, 2021ના રોજ સ્વિટઝર્લેન્ડ સ્થિત મેડિસીન્સ જર્નલ દ્વારા પ્રસિદ્ધ ચિકિત્સકીય સંશોધન પેપર અનુસાર ઉપચારની કાર્યસાધકતાની તુલના 14 દિવસ માટે ચેલ્ડર ફેટિગ સ્કેલ (સીએફક્યુ- 11)નો ઉપયોગ કરીને તુલના કરવામાં આવી હતી. રસપ્રદ રીતે 14 દિવસના નિયંત્રણ પાંખ (91 ટકા સામે 15 ટકા) સામે પરીક્ષણ દરમિયાન દર્દીઓમાં વધુ ટકાવારીમાં થાકનો ઉકેલ લાવવામાં પૂરક ઉપચાર પરિણમ્યો હતો, એમ ડો. રાઠીએ જણાવ્યું હતું.

એન્ઝાઈમ્સ અને પ્રોબાયોટિક્સ સ્ટેમિના અને વિટાલિટી પુનર્જીવિત કરવા માટે મજબૂત યંત્રણા છે, જે તાજેતરમાં પૂર્ણાહુતિ થયેલાં અડસટ્ટે ચિકિત્સકીય પરીક્ષણો દરમિયાન સિદ્ધ થયાં છે, એમ એઈટીએલના ચેરમેન શ્રી વસંત રાઠીએ જણાવ્યું હતું.

અમારા સંશોધન આધારિત સર્વ નૈસર્ગિક, રસાયણ મુક્ત કોવિડ પશ્ચાર ઈમ્યુન સપોર્ટ બંડલ ઈમ્યુનોએસઈબી અને બાયોમી અલ્ટ્રા (પ્રોબાયોએસઈબી સીએસસી૩) લોકોના હિત માટે અમારી કંપનીએ ભારત અને દુનિયાભરમાં અમારી ઓમ્નીચેનલ હાજરી વધારી દીધી હતી. અમે મહામારી વચ્ચે યુએસ બજારમાં અમારી સફળતાને ચાખી છે, આ પ્રોડક્ટ એમેઝોન પર ઉપલબ્ધ છે.

જેથી ગોળીથી કંટાળેલા, આરોગ્યવર્ધક પુખ્તો, ઈમ્યુનિટી સતર્ક નવી પેઢી અને જન ઝેડના મોટા વર્ગને ધ્યાનમાં રાખીને ભારતમાં ઓનલાઈન માર્કેટપ્લેસમાં બ્રાન્ડ્સને ટેકો આપવા માટે અમારી ફ્લેગશિપ ઈમ્યુન સપોર્ટ આપવાનું નક્કી કર્યું છે, એમ એઈટીએલના હોલ ટાઈમ ડાયરેક્ટર શ્રી મુકુંદ કાબ્રાએ જણાવ્યું હતું.

advanced enzymes
Where ENZYME is Life

MEDIA BREIFING ON 'THE RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF SYSTEMIC ENZYMES AND PROBIOTICS IN THE RESOLUTION OF POST-COVID FATIGUE'

SEPTEMBER 13, 2021

SAFE HARBOUR STATEMENT

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

advanced enzymes
Where ENZYME is Life

POST VIRAL FATIGUE

AN EXTENDED PERIOD OF FEELING UNWELL AND FATIGUED AFTER A VIRAL INFECTION

The survey done by an Office for National Statistics (ONS) United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after 12 weeks[1].

- Tiredness or Fatigue
- Joint or Muscle pain
- Difficulty in concentrating (Brain Fog)
- Difficulty in breathing
- Difficulty in thinking and concentrating
- Diarrhea
- Many other symptoms…

1. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk
2. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-47---post-covid-19-condition?gclid=CjwKCAjwyvaJBhBpEiwA8d38vMtvc_021k7od5B88oMvGRnRJoeUoYLUQpk2CWJSks_eqWQVOXDQaRoCBoIQAvD_BwE

advanced enzymes
Where ENZYME is Life

RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF SYSTEMIC ENZYMES AND PROBIOTICS IN THE RESOLUTION OF POST-COVID FATIGUE

OBJECTIVE

Objective: To evaluate the efficacy and safety of the health supplements ImmunoSEB and ProbioSEB CSC3 in patients suffering from COVID-19 induced fatigue,a randomized, multicentric, double blind, placebo-controlled trial was conducted in 200 patients with a complaint of post-COVID fatigue.

CLINICAL TRIAL

The test arm (n = 100) received the oral supplements for 14 days and the control arm (n = 100) received a placebo. Treatment efficacy was compared using the Chalder Fatigue scale (CFQ-11), at various time points from days 1 to 14. The supplemental treatment resulted in resolution of fatigue in a greater percentage of subjects in the test vs. the control arm (91% vs. 15%) on day 14.



OUTCOME

Subjects in the test arm showed a significantly greater reduction in total as well as physical and mental fatigue scores at all time points vs. the control arm. The supplements were well tolerated with no adverse events reported. This study demonstrates that a 14 days supplementation of ImmunoSEB + ProbioSEB CSC3 resolves post-COVID-19 fatigue and can improve patients' functional status and quality of life.

advanced enzymes
Where ENZYME is Life

A 200 patients Clinical study: On post COVID fatigue



Clinically validated product that helps post COVID / viral fatigue

advanced enzymes
Where ENZYME is Life

A 200 patients clinical study conducted in July 2021 on post COVID fatigue



advanced enzymes
Where ENZYME is Life

IT'S PURELY A SUPPLEMENTAL THERAPY AND NOT A "DRUG"

RESEARCHED-BACKED ALL NATURAL, CHEMICAL-FREE POST-COVID IMMUNE SUPPORT SUPPLEMENTS

ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex)

ImmunoSEB + ProbioSEB CSC3 was clinically found to be efficacious as supplemental therapy administered in mild-to-moderate COVID-19 patients as it indicated overall clinical improvement as per WHO 7-point ordinal scale

advanced enzymes
Where ENZYME is Life

Clinical study: On mild to moderate COVID-19 hospitalized patients

Days to clinical improvement, fever reduction and hospitalization days
Clinical trial was conducted on 60 patients in October 2020







C-Reactive Protein (CRP) and SPO_2 Levels





Shah N. et. al., Potential of the Combination of a Systemic Enzyme Complex and Probiotics administration to Combat COVID-19: A Randomized Open Label Prospective Analysis, Advanced in clinical Toxicology, 6,(1), 2021.

advanced enzymes
Where ENZYME is Life

A case series: On post COVID-19 fatigue







Parate R and Shah N. Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series. Med J Clin Trials Case Stud, 5(2), 2021.

advanced enzymes
Where ENZYME is Life

Effective supplementation therapy…


Reduction of post COVID-19 fatigue/ weakness


Reduction of Hospitalization Time


Improved blood oxygen saturation


Faster resolution of fever


No adverse events

*For use as dietary supplementation only

1. Shah N. et. al., Potential of the Combination of a Systemic Enzyme Complex and Probiotics administration to Combat COVID-19: A Randomized Open Label Prospective Analysis, Advanced in clinical Toxicology, 6,(1), 2021.
2. Parate R and Shah N. Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series. Med J Clin Trials Case Stud, 5(2), 2021.

advanced enzymes
Where ENZYME is Life

Other Health Studies and Publications

CLINICAL TRIALS

Maity, C., and Gupta, A. K.(2021). Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (2021) 100:3. https://doi.org/ 10.1097/MD.0000000000023641

Maity, C., & Gupta, A. K. (2018). A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. *European Journal of Clinical Pharmacology*, *75*(1), 21–31. https://doi.org/10.1007/s00228-018-2562-x

Maity, C., Gupta, A. K., Saroj, D. B., Biyani, A., Bagkar, P., Kulkarni, J., and Dixit, Y. (2020). Impact of a gastrointestinal stable probiotic supplement Bacillus Coagulans LBSC on human gut microbiome. Journal of Dietary supplements. https://doi.org/10.1080/19390211.2020.1814931

Maity, C., and Gupta, A. K.(2021). A Prospective, Interventional, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Bacillus clausii 088AE as Immunomodulator in Acute Allergic Rhinitis. CTRI/2020/09/027657 [Registered on: 08 Sep 2020] Mendeley Data, V1, doi: 10.17632/r28yk274z6.1

Maity, C., and Gupta, A. K.(2021). A Prospective Clinical Study to Evaluate the Efficacy and Safety of a Probiotic Combination of Bacillus clausii 088AE, Bacillus coagulans LBSC and Bacillus subtilis PLSSC as Immunomodulators in Acute Allergic Rhinitis. CTRI/2020/09/027657 [Registered on: 08 Sep 2020] Mendeley Data, V1, doi: 10.17632/dxx7czctmx.1

Maity, C., and Gupta, A. K.(2021). A Prospective, Interventional, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of ImmunoSEB as Immunomodulator in Acute Allergic Rhinitis, CTRI/2020/09/027657 [Registered on: 08 Sep 2020]. Mendeley Data, V1, doi: 10.17632/9c582b7rv3.1

Other Studies

Maity, C., Bagkar, P., Dixit, Y., Tiwari, A., & Gupta, A. K. (2020). Process and Storage Stability of Bacillus coagulans LBSC in Food Matrices and Appraisal of Calorific Restriction: B. coagulans LBSC stability and calorie restriction. *Applied Food Biotechnology*, *8*(1), 57-69. https://doi.org/10.22037/afb.v8i1.31212

Bagkar, P., Gupta, A., and Maity, C., (2021). Effect of high pressure processing (HPP) on spore preparation of probiotic Bacillus coagulans LBSC [DSM 17654] International Journal of Food Engineering, 000010151520200336. https://doi.org/10.1515/ijfe-2020-0336

Saroj, D. B., & Gupta, A. K. (2020). Genome based safety assessment for Bacillus coagulans strain LBSC (DSM 17654) for probiotic application. International Journal of Food Microbiology, 318,108523. https://doi.org/10.1016/j.ijfoodmicro.2020.108523

advanced enzymes
Where ENZYME is Life

The Immunity Bundle

7 Days Pack

15 Days Pack

Available on amazon

advanced enzymes
Where ENZYME is Life